The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Effective disaster response and management is a collaborative work
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Subscribe To Our Newsletter & Stay Updated
